JP2022151814A5 - - Google Patents

Download PDF

Info

Publication number
JP2022151814A5
JP2022151814A5 JP2022047297A JP2022047297A JP2022151814A5 JP 2022151814 A5 JP2022151814 A5 JP 2022151814A5 JP 2022047297 A JP2022047297 A JP 2022047297A JP 2022047297 A JP2022047297 A JP 2022047297A JP 2022151814 A5 JP2022151814 A5 JP 2022151814A5
Authority
JP
Japan
Prior art keywords
concentration
polysorbate
pharmaceutical composition
buffer
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022047297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022151814A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2022151814A publication Critical patent/JP2022151814A/ja
Publication of JP2022151814A5 publication Critical patent/JP2022151814A5/ja
Pending legal-status Critical Current

Links

JP2022047297A 2021-03-24 2022-03-23 安定な水性医薬組成物又は凍結乾燥医薬組成物 Pending JP2022151814A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021049485 2021-03-24
JP2021049485 2021-03-24

Publications (2)

Publication Number Publication Date
JP2022151814A JP2022151814A (ja) 2022-10-07
JP2022151814A5 true JP2022151814A5 (cg-RX-API-DMAC7.html) 2025-04-01

Family

ID=83395731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022047297A Pending JP2022151814A (ja) 2021-03-24 2022-03-23 安定な水性医薬組成物又は凍結乾燥医薬組成物

Country Status (10)

Country Link
US (1) US20240165258A1 (cg-RX-API-DMAC7.html)
EP (1) EP4311555A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022151814A (cg-RX-API-DMAC7.html)
KR (1) KR20230160848A (cg-RX-API-DMAC7.html)
CN (1) CN116997352A (cg-RX-API-DMAC7.html)
AU (1) AU2022245592B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023019201A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214463A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011087A (cg-RX-API-DMAC7.html)
WO (1) WO2022202947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335459A4 (en) * 2021-05-12 2025-05-07 JCR Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of mucopolysaccharidosis type 1
CN121793950A (zh) * 2023-09-14 2026-04-03 株式会社绿十字 新的含有α-半乳糖苷酶A融合蛋白的冻干制剂
KR20250081554A (ko) * 2023-11-29 2025-06-05 주식회사 에스엔바이오사이언스 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법
WO2025229980A1 (ja) * 2024-05-01 2025-11-06 Jcrファーマ株式会社 凍結乾燥製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
CN101674805A (zh) * 2007-05-02 2010-03-17 诺沃-诺迪斯克保健股份有限公司 包括芳香族防腐剂和抗氧化剂的高浓度因子ⅶ多肽制剂
JP6279466B2 (ja) 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
CN110022855B (zh) * 2016-10-07 2024-07-16 瑞泽恩制药公司 室温稳定的冻干蛋白质
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
JOP20190162A1 (ar) * 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
WO2019049967A1 (ja) * 2017-09-07 2019-03-14 Jcrファーマ株式会社 水性医薬組成物
EP4335459A4 (en) * 2021-05-12 2025-05-07 JCR Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of mucopolysaccharidosis type 1

Similar Documents

Publication Publication Date Title
TWI797073B (zh) 包含雙特異性抗體建構物之醫藥組合物
TWI911431B (zh) 抗rsv單株抗體配製物
JP2024099682A5 (cg-RX-API-DMAC7.html)
JP2021512881A5 (cg-RX-API-DMAC7.html)
US6403098B1 (en) Rotavirus vaccine formulations
US6616931B1 (en) Rotavirus vaccine formulations
JP2022174082A5 (cg-RX-API-DMAC7.html)
US5932223A (en) Rotavirus vaccine formulations
JP2024099628A5 (cg-RX-API-DMAC7.html)
JP2025148550A5 (cg-RX-API-DMAC7.html)
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
JP2018188437A5 (cg-RX-API-DMAC7.html)
JP2010511665A5 (cg-RX-API-DMAC7.html)
TW201711699A (zh) 一種抗pd-1抗體製劑及其在醫藥上的應用
JP2009524595A5 (cg-RX-API-DMAC7.html)
CN102740889A (zh) 用于预防或抑制艰难梭菌感染的疗法
TW201223541A (en) Liquid formulations of long acting interferon alpha conjugate
EP0939648B1 (en) Rotavirus vaccine formulations
JP2019509311A5 (cg-RX-API-DMAC7.html)
JP2024540377A5 (cg-RX-API-DMAC7.html)
TWI617324B (zh) 高度濃縮之長效人類生長激素共軛物之液體製劑
JP2024167394A (ja) 製剤
JP2024522855A5 (cg-RX-API-DMAC7.html)
TW201735940A (zh) 長效人類生長激素共軛物之新穎液體調配物
JP2020506882A (ja) 炎症性障害の治療療法